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A Novel Phenotype of Nonsteroidal Anti-Inflammatory
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Background: Some nonsteroidal anti-inﬂammatory drug (NSAID)Y
hypersensitive patients develop adverse reactions when challengedwith
weak cyclooxygenase 1 (COX-1) inhibitors.
Objectives: To investigate the prevalence and clinical features of
this high-risk population.
Materials and Methods: Patients from 2 outpatient allergy clinics
consulting between October 2005 and October 2007 because of ad-
verse reactions to classic NSAIDs were submitted to conﬁrmatory
double-blind oral challenges with the suspected NSAID and with
acetaminophen, preferential and/or speciﬁc COX-2 inhibitors.
Patients were then classiﬁed as low-risk and high-risk groups ac-
cording to the results of provocation tests.
Results: Three hundred three patients were studied: 179 (59.0%)
were tolerant to acetaminophen and the selective COX-2 inhibi-
tors (low-risk group), whereas 124 (40.9%) developed reactions to
at least one of the ‘‘low COX-1 inhibitors’’ (high-risk group). No
distinctive demographic or clinical characteristics were present
when both groups of patients were compared.
Conclusions: A large proportion of patients sensitive to classic
NSAIDs cannot tolerate the weak COX-1 inhibitors. Oral chal-
lenges should be performed by trained specialists to advise these
patients about the use of NSAIDs.
Key Words: aspirin, angioedema, cyclooxygenases,
NSAIDs, urticaria
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Hypersensitivity reactions to aspirin and nonsteroidal anti-inﬂammatory drugs (NSAIDs) are common in the pop-
ulation, and they are observed more often in young atopic
individuals.1 Different clinical patterns of reactions involving
the skin, respiratory tract, or generalized have been described,
and 4 forms of clinical presentation have been proposed: (1)
respiratory (aspirin-exacerbated respiratory disease), (2) cuta-
neous (urticaria and angioedema), (3) mixed, and (4) systemic
(anaphylaxis).2
Because many patients will react to NSAIDs of diverse
chemical composition (cross reactions), it is unlikely that most
of these reactions are mediated by speciﬁc immunologic
mechanisms and it has been postulated that they are caused by
inhibition of the isoenzyme cyclooxygenase 1 (COX-1),
leading to excessive production of cysteinyl leukotrienes and
a decreased synthesis of prostaglandin E2.3,4 In consequence,
the new NSAIDs that selectively inhibit COX-2 and
purportedly do not inhibit COX-1 were tested in NSAID-
sensitive patients, and it was observed that preferential and
speciﬁc COX-2 inhibitors were tolerated by most of them.5
There is, however, a subset of patients who develop ad-
verse reactions when challenged with conventional doses of
COX-2 inhibitors.6Y9 Matucci et al10 recently proposed that
patients reacting to Blow COX inhibitors[ such as acetamino-
phen and nimesulide should be designated as a high-risk pop-
ulation of NSAID-hypersensitive patients. The present
investigation was performed to determine the prevalence and
clinical characteristics of this subpopulation at high risk of
reactions to low COX-1 inhibitors.
MATERIALS AND METHODS
All patients attending 2 outpatient allergy clinics in Ca-
racas between October 2005 and October 2007 and complain-
ing of urticaria, angioedema, asthma, or anaphylaxis occurring
after taking NSAIDs were included in the study. Information
on age, sex, history of allergic diseases, and drugs provoking
the symptoms was obtained by direct patient questioning.
After signing informed consent forms, they were submitted to
double-blind placebo-controlled oral challenges with classic
and selective NSAIDs8 and to skin prick tests with inhalant
allergens (ALK Abello´, Madrid, Spain).
Oral challenges were performed by means of a double-
masked protocol. The drugs or placebo, given on different
days, were concealed in identical opaque capsules, and half
doses were administered 1 hour apart, with 3 hours of ob-
servation in the hospital and a telephone recall 24 hours later.
Vital signs and pulmonary function (forced expiratory vol-
ume in 1 second, forced vital capacity, forced expiratory ﬂow
between 25% and 75%, and peak expiratory ﬂow) were mo-
nitored at baseline and hourly for 3 hours, and the skin, nose,
eyes, and thorax were examined at the same time intervals.
The presence of breathlessness, cough, wheezing, dysphonia,
nasal or ocular itching, sneezing, rhinorrhea, nasal obstruc-
tion, and conjunctival erythema was speciﬁcally investigated
at every hourly physical examination. For urticaria and
angioedema, the percentage of skin involved was calculated
as follows: head and neck, 30%; chest, 20%; abdomen, 20%;
upper limbs, 15%; and lower limbs, 15%. The test result was
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regarded as positive for urticaria or angioedema if involve-
ment of 20% or more of the body surface area was present; and
for respiratory reactions, if symptoms or signs appeared or a
decrease in forced expiratory volume in 1 second greater than
20% of the basal condition was detected. Patients were
challenged during remission of the urticaria or angioedema
and with antihistamines and leukotriene modiﬁers withheld for
at least 96 hours before testing. Corticosteroids were omitted
1 month before testing. Maximal challenge doses were:
acetaminophen 500 mg, nimesulide 100 mg, meloxicam
15mg, celecoxib 200mg, rofecoxib 50 mg, etoricoxib
120mg, and valdecoxib 40 mg. The protocol was approved
by the institutional review boards of the participating
institutions. The pharmacological and clinical pattern of the
reactions was established as previously described.2
Statistical Analysis
Mean values were compared using Student t test. Pro-
portions were compared using Fisher exact test.
RESULTS
During the period of the study, 303 patients with
challenge-conﬁrmed NSAID hypersensitivity reactions were
observed. One hundred seventy-nine (59.0%) reacted to clas-
sic NSAIDs but tolerated acetaminophen and one or more
selective or speciﬁc COX-2 inhibitors (low-risk group). One
hundred twenty-four patients (40.9%) were classiﬁed as the
high-risk group based on positive oral challenges to acet-
aminophen and selective or speciﬁc COX-2 inhibitors (Fig. 1).
Table 1 shows the demographic and clinical characteristics
of the 2 groups of patients. Drugs responsible for reactions
to low COX inhibitors observed in the high-risk group are
shown in Figure 2, where it can be observed that the order
of frequency of reactions was: acetaminophen, nimesulide,
meloxicam, celecoxib, rofecoxib, etoricoxib, and valdecoxib.
It must be mentioned, however, that the number of chal-
lenges was not the same for all the selective drugs, and there-
fore these data must be interpreted with caution.
A case report is included to illustrate the clinical
presentation of a patient of the high-risk subset.
Case Report
S.S.F. is a 66-year-old female patient who complained of
eyelid angioedema, ocular itching, and facial and cervical
erythema that occurred into the ﬁrst 30 minutes after receiving
various analgesics, including aspirin, pyrazolone, and keto-
profen. According to the patterns previously proposed, this
patient was pharmacologically classiﬁed as cross-reactor and
clinically, because of the presence of cutaneous and ocular
symptoms, as mixed (blended). There was no history of
other allergic or atopic diseases, and immediate-type skin
hypersensitivity (prick) tests with 20 inhalant and 21 food
allergens were negative. Double-blind oral provocation test
results were as follows:
Meloxicam
One hour after receiving 7.5 mg of meloxicam, eyelid
edema, breathlessness, dysphonia, and a sensation of laryn-
geal swelling were reported by the patient. Treatment with
FIGURE 1. Patients with NSAID hypersensitivity classiﬁed
according to the risk of reactions to low COX inhibitors.
TABLE 1. Demographic and Clinical Features of Patients





n 179 124 V
Age T SD (range), y 30.6 T 12.8 (9Y69) 32.7 T 14.5 (10Y90) 0.18
Sex, n (%)
Female 120 (67.0) 93 (75.0) V
Male 59 (32.9) 31.0 (25.0) 0.1
Atopic disease, n (%)
Any atopic disease 162 (90.5) 104 (83.8) V
Rhinitis 117 (65.3) 76 (61.2) V
Rhinitis and asthma 41 (22.9) 26 (20.9) V
Asthma 2 (1.1) 1 (0.8) V
Rhinitis, asthma,
and dermatitis
2 (1.1) 0 (0) V
Rhinitis and dermatitis 0 (0) 1 (0.8) V
None 17 (9.4) 20 (16.1) 0.1
Pharmacological pattern, n (%)
Cross reactor 146 (81.5) 92 (74.1) V
Single reactor 33 (18.4) 32 (25.8) 0.1
Clinical pattern, n (%)
Cutaneous 99 (55.3) 61 (49.1) 0.3
Mixed 79 (44.1) 62 (50.0) 0.3
Systemic 1 (0.5) 1 (0.8) 0.6
Immediate-type
skin tests, +/n (%)
148/173 (85.5) 97/105 (92.3) 0.1
FIGURE 2. Frequency of reactions to low COX inhibitors in
124 patients with a high risk of reactions to NSAIDs.
Sa´nchez-Borges et al WAO Journal & February 2009
18 * 2009 World Allergy Organization
epinephrine (1:1000) 0.3 mL subcutaneously and chlorphenir-
amine 100 mg intravenously were administered. The patient
was discharged after total recovery 2 hours later.
Celecoxib
Thirty minutes after a 100-mg provocative dose of
celecoxib, an itchy erythematous rash was observed in the face,
neck, and chest (Fig. 3A). Oral chlorpheniramine 8 mg and
montelukast 10 mg induced the disappearance of the rash in
approximately 30 minutes.
Nimesulide
A challenge with 100 mg was tolerated (Fig. 3B).
DISCUSSION
A subset of patients with hypersensitivity to NSAIDs
cannot tolerate drugs that weakly inhibit COX-1. The reasons
for these reactions are presently not clear, and this study
intended to investigate the proportion of NSAID-sensitive
patients who show an increased risk of reactions to acet-
aminophen and selective COX-2 inhibitors, the high-risk
subpopulation of individuals proposed by Matucci et al,10
and to determine the clinical features that could help identify
these patients.
As shown in Table 1, there were no distinctive clinical
characteristics permitting to distinguish among low-risk and
high-risk patients, including age, sex, presence of atopic dis-
eases, positivity of immediate-type skin hypersensitivity tests
with inhalant allergens, and pharmacological or clinical
pattern.
The proportion of patients who reacted to weak COX
inhibitors in this series was 40.9%, a considerable and
important ﬁgure. Interestingly, among low COX inhibitors,
acetaminophen was most commonly incriminated, followed by
nimesulide, meloxicam, and less frequently, the coxibs, the
more selective drugs sparing COX-1 (Fig. 2). This is in
agreement with the rates of inhibition of COX-1 in vitro,11
with the exception of acetaminophen that inhibits another
isoenzyme, COX-3, which is closely related to COX-1.12Y14
The management of pain and inﬂammation in low-risk
patients was accomplished with selective NSAIDs according
to the results of oral challenges. In general, these patients
continue to tolerate treatment with low COX inhibitors,
although it has been occasionally reported that some patients
will develop later on reactions with drugs that had been
tolerated during controlled challenges.15 In high-risk patients,
such as the one described in this article, the management is
more difﬁcult, and in many of them, it is limited to the use of
opioids for postsurgical pain and alternative analgesic
methods such as acupuncture and others. Additional research
is needed to offer new therapies to these patients with a high
risk of reactions to NSAIDs.
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FIGURE 3. A 66-year-old female NSAID-sensitive patient after
oral challenge with (A) celecoxib and (B) nimesulide.
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